Tourmaline Bio’s Post

#Day1 of European Association for the Study of Diabetes #EASD2024 In my oral presentation, I presented the results of our study concerning cardiovascular risk estimation in people with type 1 diabetes using optical coherence tomography (OCT). We found that all 12/62 asymptomatic patients had very severe OCT findings through thin-cap fibroatheroma and other high-risk lesions and, therefore, should be treated as very high-risk patients. Thanks a lot to all co-workers from our Diabetes Centre IKEM and the Department of Cardiology IKEM, especially to Robert Roland, Michal Pazderník_Prague ICU and Peter Wohlfahrt. Prof. Martin Haluzík presented data about how switching people with type 2 diabetes from mixed insulins to iGlarLixi is a safe and effective treatment approach with improved glycemic outcomes, weight benefits and no increased risk of hypoglycemia. #diabetes #cardiovascular #type1DM #type2DM

The recent CVOT Summit Report 2023 shed light on groundbreaking outcomes trials in cardiovascular, kidney, and metabolic health. Discussions highlighted advancements in managing major adverse cardiovascular events and obesity-related heart failure. The summit also explored innovative strategies for diabetes, chronic kidney disease, and obesity treatment. Emphasizing inclusivity in clinical trials and patient-centered care, this report is a must-read for healthcare professionals seeking the latest developments in managing diabetes and associated comorbidities. #CVOTSummit #Cardiology

According to a recent study in the International Journal of Cardiology, patients who use proton pump inhibitors (PPIs) are at increased risk for cardiovascular disease, and clinicians should therefore exercise caution when prescribing PPIs. https://lnkd.in/gqfKC9pn Not everyone who is prescribed PPIs needs them. This is why objective testing - like with Restech - is so important in reflux diagnostics. PPIs provide invaluable relief for patients in need, but doubt has been cast on their safety and efficacy as a long term solution. This highlights the role that antireflux endoscopic therapy such as minimally invasive Stretta can play in long term reflux care. #reflux #testbeforeyoutreat #PPIs #CVD #cardiovasculardisease

New research sheds light on the impact of inflammatory markers and polyvascular atherosclerotic disease on patient outcomes post-PCI. Discover how elevated hsCRP levels and PolyVD status affect major adverse cardiovascular events in this insightful study. Learn more in the June 2024 issue of Cardiology by Bay et al. #CardiologyResearch #Inflammation #PatientOutcomes #PCI #CardiovascularHealth

Dedicated issue from JACC Journals focuses on the burden of cardiovascular disease (CVD) across twenty-one global regions from 1990 to 2022 using Global Burden of Disease data 🫀 American College of Cardiology Read the report ➪ https://bit.ly/48kuyUe

Did you know that Diabetes could increase the risk of heart failure by 2 to 5 times? The European Society of Cardiology (ESC) 2023 guidelines highlight the importance of testing patients with diabetes for cardiovascular disease. The LumiraDx Platform offers both #NTproBNP and #HbA1c testing from a simple fingerstick sample on one portable Platform, giving accurate results in minutes. Click here to learn more: https://lnkd.in/eYxR-HfS

We'll be presenting topline data from our registration-enabling Phase 3 LIBerate 006 study at the American College of Cardiology 2024 (#ACC24). The results demonstrate Lerodalcibep's impact on LDL-C, a robust predictor of future cardiovascular risk events, in patients with, or at very-high or high risk, for cardiovascular disease on stable lipid-lowering therapy. https://lnkd.in/gNHk_fkx

Coronary angioplasty is a procedure to open clogged blood vessels of the heart. Coronary angioplasty treats vessels, called coronary arteries, which deliver blood to heart muscles. On 16 September 1977 the first coronary angioplasty was performed by Dr. Andreas Grüntzig at the University Hospital Zurich in Switzerland. Since then, angioplasty has been the procedure that improves health, increases life expectancy and improves the quality of life.   16 September is the International Day for Interventional Cardiology to raise public awareness of cardiovascular diseases, procedures, related complications, prevention and care. Prove Clinical Labs is well equipped to support Phase I-III Clinical Trials in Cardiovascular Diseases. Find out more about Prove labs and how we can support your clinical trial by visiting: www.provelabs.com #cardiovascular #heartdisease #clinicalresearch #centrallab

New study highlights benefits of CRT-D in non-ischemic cardiomyopathy patients! Cardiac resynchronisation therapy (CRT) has long been heralded as a breakthrough for heart failure patients with electrical desynchrony. A recent meta-analysis comparing CRT with implantable cardioverter-defibrillator (CRT-D) to CRT with pacemaker only (CRT-P) in non-ischemic cardiomyopathy (NICM) patients sheds light on its efficacy. The study, pooling data from 13 studies and over 61,000 patients, found that CRT-D significantly lowers the risk of all-cause mortality compared to CRT-P (pooled HR 0.74; 95% CI: 0.62-0.88). However, this benefit was not observed in patients older than 75 years. While CRT-D didn't show a significant reduction in cardiovascular mortality, its impact on overall survival underscores its importance in managing NICM. More details from the full article here: https://bit.ly/3yzELz4 #HeartFailure #CRTTherapy #Defibrillator #Cardiomyopathy

💓 Improving Heart Health: A Multimodality Approach to Chagas Disease🩺 We're excited to share Exploration of Cardiology (EC) journal's latest publication, which presents a comprehensive strategy for managing dilated cardiomyopathy in Chagas disease. This innovative research offers valuable insights into enhancing patient care. 🔬 Key Focus: Multimodality Strategy: Our study outlines a multifaceted approach to treating dilated cardiomyopathy, a common complication of Chagas disease. Patient-Centered Care: By combining various treatment modalities, we aim to improve the quality of life for patients suffering from this condition. Clinical Implications: This research provides healthcare professionals with a roadmap for more effective management of Chagas disease-related heart issues. 🌟 Why It Matters: Chagas disease affects millions worldwide, and this study could be a game-changer in the way we approach treatment and care for affected individuals. 📚 Read the Full Article: https://lnkd.in/gYiFy-b3 💡 Join the Conversation: We invite you to explore our findings and engage in discussions on advancing cardiovascular care. Your insights are invaluable to our community. #Cardiology #ChagasDisease #PatientCare #ECJournal